PE20220297A1 - Neutralizacion del virus chikungunya mediada por anticuerpos - Google Patents

Neutralizacion del virus chikungunya mediada por anticuerpos

Info

Publication number
PE20220297A1
PE20220297A1 PE2022000095A PE2022000095A PE20220297A1 PE 20220297 A1 PE20220297 A1 PE 20220297A1 PE 2022000095 A PE2022000095 A PE 2022000095A PE 2022000095 A PE2022000095 A PE 2022000095A PE 20220297 A1 PE20220297 A1 PE 20220297A1
Authority
PE
Peru
Prior art keywords
chikungunya virus
antibody
mediated neutralization
neutralization
mediated
Prior art date
Application number
PE2022000095A
Other languages
English (en)
Inventor
James E Crowe
Scott A Smith
Terence Dermody
Laurie Silva
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of PE20220297A1 publication Critical patent/PE20220297A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)

Abstract

Anticuerpos que se unen y neutralizan al virus Chikungunya (CHIKV), hibridomas que los codifican, metodos para detectar una infeccion por el virus Chikungunya que los emplean, usos de los mismos, composicion farmaceutica que los comprende, linea celular que los produce, metodo para producirlos y kit que los comprende
PE2022000095A 2015-04-14 2016-04-14 Neutralizacion del virus chikungunya mediada por anticuerpos PE20220297A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147354P 2015-04-14 2015-04-14
PCT/US2016/027466 WO2016168417A2 (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus

Publications (1)

Publication Number Publication Date
PE20220297A1 true PE20220297A1 (es) 2022-03-07

Family

ID=57126199

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022000095A PE20220297A1 (es) 2015-04-14 2016-04-14 Neutralizacion del virus chikungunya mediada por anticuerpos
PE2017002105A PE20180171A1 (es) 2015-04-14 2016-04-14 Neutralizacion del virus chikungunya mediada por anticuerpos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017002105A PE20180171A1 (es) 2015-04-14 2016-04-14 Neutralizacion del virus chikungunya mediada por anticuerpos

Country Status (28)

Country Link
US (2) US10787503B2 (es)
EP (1) EP3283101A4 (es)
JP (3) JP6979875B2 (es)
KR (2) KR20230087616A (es)
CN (2) CN114478756A (es)
AR (1) AR104264A1 (es)
AU (2) AU2016250188C1 (es)
BR (1) BR112017021952A2 (es)
CA (2) CA2982491C (es)
CL (1) CL2017002596A1 (es)
CO (1) CO2017010316A2 (es)
CR (2) CR20170518A (es)
DO (1) DOP2017000236A (es)
EA (1) EA037060B1 (es)
EC (1) ECSP17075750A (es)
HK (1) HK1246671A1 (es)
IL (2) IL290449B2 (es)
MA (1) MA41517A (es)
MX (2) MX2017013286A (es)
MY (1) MY191666A (es)
NZ (1) NZ736445A (es)
PE (2) PE20220297A1 (es)
PH (1) PH12017501865A1 (es)
SG (2) SG10202107295XA (es)
TN (1) TN2017000438A1 (es)
TW (2) TW202248210A (es)
UA (1) UA125206C2 (es)
WO (1) WO2016168417A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
KR102029394B1 (ko) * 2017-11-14 2019-10-07 재단법인 바이오나노헬스가드연구단 치쿤구니아 바이러스 감염 진단용 단일클론항체, 이를 생산하는 하이브리도마 및 이를 이용한 치쿤구니아 바이러스 감염 진단 방법
EP3735270A1 (en) 2018-01-05 2020-11-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019156758A2 (en) * 2018-01-05 2019-08-15 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
JP6906207B2 (ja) * 2018-02-09 2021-07-21 国立大学法人大阪大学 チクングニアウイルス検出用免疫クロマト分析装置
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
US20220265806A1 (en) * 2018-06-06 2022-08-25 Albert Einstein College Of Medicine, Inc Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
WO2021042021A1 (en) * 2019-08-31 2021-03-04 Vanderbilt University Human antibodies to alphaviruses
KR102202082B1 (ko) * 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN110922478B (zh) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
WO2022101805A1 (en) * 2020-11-13 2022-05-19 Emergent Biosolutions Canada Inc. Hyperimmune globulins for treatment of chikungunya virus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
EP3021868A4 (en) * 2013-07-19 2017-03-01 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途

Also Published As

Publication number Publication date
HK1246671A1 (zh) 2018-09-14
WO2016168417A2 (en) 2016-10-20
KR20180004403A (ko) 2018-01-11
MX2017013286A (es) 2018-06-19
CR20210438A (es) 2021-10-04
PH12017501865A1 (en) 2018-03-05
AR104264A1 (es) 2017-07-05
UA125206C2 (uk) 2022-02-02
EA201792220A1 (ru) 2018-03-30
IL254891B (en) 2022-03-01
AU2022202819A1 (en) 2022-05-19
JP2021144047A (ja) 2021-09-24
CL2017002596A1 (es) 2018-05-18
MX2021013207A (es) 2021-12-10
DOP2017000236A (es) 2017-12-15
ECSP17075750A (es) 2018-02-28
JP6979875B2 (ja) 2021-12-15
AU2016250188C1 (en) 2022-08-11
IL254891A0 (en) 2017-12-31
SG11201708152SA (en) 2017-11-29
CA3176525A1 (en) 2016-10-20
TW201643189A (zh) 2016-12-16
SG10202107295XA (en) 2021-08-30
IL290449B1 (en) 2023-12-01
NZ736445A (en) 2023-06-30
KR102541905B1 (ko) 2023-06-12
AU2016250188B2 (en) 2022-02-03
IL290449A (en) 2022-04-01
CO2017010316A2 (es) 2017-12-15
CR20170518A (es) 2018-01-25
KR20230087616A (ko) 2023-06-16
CN114478756A (zh) 2022-05-13
MA41517A (fr) 2017-12-19
WO2016168417A3 (en) 2017-01-05
EA037060B1 (ru) 2021-02-01
MY191666A (en) 2022-07-06
TW202248210A (zh) 2022-12-16
CN107708726B (zh) 2022-01-14
CA2982491C (en) 2023-08-29
AU2016250188A1 (en) 2017-11-02
JP2018520334A (ja) 2018-07-26
EP3283101A4 (en) 2019-01-16
PE20180171A1 (es) 2018-01-22
US20180079802A1 (en) 2018-03-22
US11345743B2 (en) 2022-05-31
TWI772257B (zh) 2022-08-01
EP3283101A2 (en) 2018-02-21
US10787503B2 (en) 2020-09-29
US20200277359A1 (en) 2020-09-03
JP2022174144A (ja) 2022-11-22
CA2982491A1 (en) 2016-10-20
CN107708726A (zh) 2018-02-16
IL290449B2 (en) 2024-04-01
TN2017000438A1 (en) 2019-04-12
BR112017021952A2 (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
ECSP19009170A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CL2018000490A1 (es) Anticuerpos anti-pd1 y sus métodos de uso
CL2017002728A1 (es) Método para el tratamiento de cáncer
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CU20180062A7 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CL2018000883A1 (es) Moduladores del receptor x farnesoide
PE20180672A1 (es) Anticuerpos anti-ctla-4 y metodos de uso de los mismos
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
PE20181367A1 (es) Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso